NICE u-turn backs Roche's Tecentriq for triple negative breast cancer

22nd May 2020 Uncategorised 0

Tecentriq is the first and only immune checkpoint inhibitor which has been deemed a cost effective use of NHS resources for this patient group

More: NICE u-turn backs Roche's Tecentriq for triple negative breast cancer
Source: News